000			02015 a2200529 4500
005			20250515011134.0
264		0	_c20060120
008			200601s 0 0 ger d
022			_a1661-8157
024	7		_a10.1024/0369-8394.94.48.1907 _2doi
040			_aNLM _beng _cNLM
100	1		_aMaier, K-P
245	0	0	_a[Drug therapy in chronic liver disease]. _h[electronic resource]
260			_bPraxis _cNov 2005
300			_a1907-12 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_aAdenine _xadministration & dosage
650	0	4	_aAdministration, Oral
650	0	4	_aAnti-HIV Agents _xadministration & dosage
650	0	4	_aAntiviral Agents _xadministration & dosage
650	0	4	_aAzathioprine _xadministration & dosage
650	0	4	_aCholangitis, Sclerosing _xdrug therapy
650	0	4	_aChronic Disease
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFatty Liver _xdrug therapy
650	0	4	_aHemochromatosis _xdrug therapy
650	0	4	_aHepatitis B, Chronic _xdrug therapy
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHepatitis, Autoimmune _xdrug therapy
650	0	4	_aHepatolenticular Degeneration _xdrug therapy
650	0	4	_aHumans
650	0	4	_aImmunosuppression Therapy
650	0	4	_aInterferons _xadministration & dosage
650	0	4	_aLamivudine _xadministration & dosage
650	0	4	_aLiver Cirrhosis, Biliary _xdrug therapy
650	0	4	_aLiver Diseases _xdrug therapy
650	0	4	_aOrganophosphonates _xadministration & dosage
650	0	4	_aPrednisolone _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aProspective Studies
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aReverse Transcriptase Inhibitors _xadministration & dosage
650	0	4	_aRibavirin _xadministration & dosage
650	0	4	_aTime Factors
773	0		_tPraxis _gvol. 94 _gno. 48 _gp. 1907-12
856	4	0	_uhttps://doi.org/10.1024/0369-8394.94.48.1907 _zAvailable from publisher's website
999			_c15974127 _d15974127